131 related articles for article (PubMed ID: 9803483)
1. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
Nagyová A; Raslová K; Ginter E
Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
[TBL] [Abstract][Full Text] [Related]
2. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
[TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
[TBL] [Abstract][Full Text] [Related]
4. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
5. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Turpin G; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
[TBL] [Abstract][Full Text] [Related]
7. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Chapman MJ; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
[TBL] [Abstract][Full Text] [Related]
8. LDL oxidizability and antioxidative status of plasma in vegetarians.
Nagyová A; Kudlácková M; Grancicová E; Magálová T
Ann Nutr Metab; 1998; 42(6):328-32. PubMed ID: 9895420
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
Collinson PO; Hjelm CJ; Canepo-Anson R
Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
[No Abstract] [Full Text] [Related]
10. Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein.
Huang JM; Huang ZX; Zhu W
Clin Biochem; 1998 Oct; 31(7):537-43. PubMed ID: 9812173
[TBL] [Abstract][Full Text] [Related]
11. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
12. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
Betteridge DJ; O'Bryan-Tear CG
Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
[TBL] [Abstract][Full Text] [Related]
13. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients.
Beaudeux JL; Guillausseau PJ; Peynet J; Flourie F; Assayag M; Tielmans D; Warnet A; Rousselet F
Clin Chim Acta; 1995 Aug; 239(2):131-41. PubMed ID: 8542651
[TBL] [Abstract][Full Text] [Related]
14. Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification.
Ishikawa T; Suzukawa M; Ito T; Yoshida H; Ayaori M; Nishiwaki M; Yonemura A; Hara Y; Nakamura H
Am J Clin Nutr; 1997 Aug; 66(2):261-6. PubMed ID: 9250103
[TBL] [Abstract][Full Text] [Related]
15. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Petit D; Bonnefis MT; Rey C; Infante R
Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of serum lipids to copper-induced peroxidation correlates with the level of high density lipoprotein cholesterol.
Shimonov M; Pinchuk I; Bor A; Beigel I; Fainaru M; Rubin M; Lichtenberg D
Lipids; 1999 Mar; 34(3):255-9. PubMed ID: 10230719
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia.
Córdoba-Porras A; Sánchez-Quesada JL; González-Sastre F; Ordóñez-Llanos J; Blanco-Vaca F
J Mol Med (Berl); 1996 Dec; 74(12):771-6. PubMed ID: 8974018
[TBL] [Abstract][Full Text] [Related]
18. [Oxidation of low-density lipoproteins. Correlation between reduced resistance in vitro and increased oxidation in vivo].
Maggi E; Falaschi F; Perani G; Frattoni A; Finardi G; Bellomo G
Presse Med; 1995 Mar; 24(9):431-6. PubMed ID: 7746815
[TBL] [Abstract][Full Text] [Related]
19. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein.
McDowell IF; McEneny J; Trimble ER
Ann Clin Biochem; 1995 Mar; 32 ( Pt 2)():167-74. PubMed ID: 7785944
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients.
Chen MF; Hsu HC; Lee YT
Cardiovasc Drugs Ther; 1997 Dec; 11(6):787-93. PubMed ID: 9512874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
